Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
CATrends: Deceptive ‘Plant-Based’ Claims
A deceptive marketing trend takes root.
TINA.org Joins Over 300 Orgs. in Letter Urging Congress to Support Financial Watchdog
Legislators should protect the work of the Consumer Financial Protection Bureau.
Happy Howl Dog Food
What does “human-grade” dog food actually mean?
Plaintiffs Awarded $2.3 Million for Bigelow Made in USA Claim Steeped in Deception
The statement, “Manufactured in the USA 100%,” had appeared on product packaging.
Stellantis pulls Jeep, Ram and Dodge tariff-response ads after built-in-USA scrutiny
E.J. Schultz, Ad Age